All In Biotech

Drug Trial Radar · NCT05562947

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

A Phase III, Multicenter, Randomized, Visual Assessor-masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Chinese Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Jun 17, 2024

Primary completion

Jun 30, 2027

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.

Conditions

  • Neovascular Age-related Macular Degeneration
  • nAMD

Interventions

  • PDS With Ranibizumab (100 mg/mL)Device

    Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100 mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.

  • Ranibizumab (10 mg/mL)Drug

    Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterwards, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44 and bi-monthly visits thereafter, followed by visits every two months until study completion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Averaged Over Weeks 36 and 40, as Assessed Using the ETDRS Visual Acuity (VA) Chart at a Starting Distance of 4 MetersTime frame: Baseline up to Week 40

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • Beijing Tongren Hospital

    Beijing, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, China

  • Qingdao Eye Hospital of Shandong First Medical University

    Qingdao, China

  • Shanghai First People's Hospital

    Shanghai, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, China

  • Shanxi Eye Hospital

    Taiyuan, China

  • Tianjin Medical University Eye Hospital

    Tianjin, China

  • Eye Hospital, Wenzhou Medical University

    Wenzhou, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Xi'an People's Hospital (Xi'an Fourth Hospital)

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.